论文部分内容阅读
目的探讨化疗联合清肺合剂改善非小细胞肺癌患者免疫功能的作用,为临床治疗提供参考依据。方法选取2015年8月—2016年1月在浙江省肿瘤医院肿瘤科治疗的晚期非小细胞肺癌患者100例,运用随机数字表法随机分为对照组(50例)和观察组(50例)。对照组采用去甲长春花碱~+顺铂化疗,观察组采用在对照组化疗治疗的基础上联合清肺合剂治疗。对比分析2组患者T淋巴细胞亚群变化、治疗后生活质量改善状况及不良反应状况。结果治疗前观察组与对照组患者的CD3~+、CD3~++CD4~+、CD3~++CD8~+、CD3~++CD4~+/CD3~++CD8~+的比值、NK细胞的百分率比较,差异不具有统计学意义(P>0.05)。治疗后,观察组患者CD3~+、CD3~++CD4~+、NK细胞的百分率较对照组显著增高,差异均具有统计学意义(P<0.05)。治疗后观察组患者生活质量提高和稳定的患者比率(96.00%)显著显著优于对照组(60.00%)(P<0.05)。白细胞减少、血小板减少、贫血、胃肠道症状和肝损伤等不良反应发生率显著低于对照组(P<0.05)。结论清肺合剂可以通过调节非小细胞肺癌患者的免疫功能,降低免疫抑制,增强机体的免疫防御机制,改善患者预后,值得在临床联合应用。
Objective To investigate the effect of chemotherapy combined with Qingfei mixture in improving immune function in patients with non-small cell lung cancer and provide reference for clinical treatment. Methods One hundred patients with advanced non-small cell lung cancer who were treated in Department of Oncology, Zhejiang Cancer Hospital from August 2015 to January 2016 were randomly divided into control group (50 cases) and observation group (50 cases) . The control group was treated with vinorelbine ~ + cisplatin, and the observation group was treated with the combination of Qingfei Mixture on the basis of the control chemotherapy. The changes of T lymphocyte subsets, quality of life improvement and adverse reactions after treatment were compared between the two groups. Results Before treatment, the ratio of CD3 +, CD3 + + CD4 +, CD3 + + CD8 +, CD3 + + CD4 + / CD3 + + CD8 + The difference was not statistically significant (P> 0.05). After treatment, the percentage of CD3 ~ +, CD3 ~ + + CD4 ~ + and NK cells in the observation group was significantly higher than that in the control group, with statistical significance (P <0.05). After treatment, the patients with observed quality of life improved and stable (96.00%) was significantly better than the control group (60.00%) (P <0.05). Leukopenia, thrombocytopenia, anemia, gastrointestinal symptoms and liver injury and other adverse reactions was significantly lower than the control group (P <0.05). Conclusion Qingfei Mixture can regulate the immune function, reduce the immunosuppression, enhance the body’s immune defense mechanism and improve the prognosis of patients with non-small cell lung cancer, which deserves to be used clinically.